

Frontier Pharma Ophthalmology Therapeutic and Overview Pipeline Review H2

Frontier Pharma Ophthalmology Treatment Pipeline Review H2 2016

PUNE, INDIA, November 15, 2016 /EINPresswire.com/ -- The visual system, including the eye and its surrounding structures, can be affected by a number of pathological conditions. Ophthalmology encompasses a diverse range of indications affecting this system. Key diseases within this therapy area include glaucoma, age-related macular degeneration, diabetic macular edema, diabetic retinopathy and dry eye syndrome.



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/744722-frontier-pharma-ophthalmology-therapeutics-leading-the-way> □

While treatments for dry eye syndrome are generally able to control its symptoms in the majority of patients, the other four diseases are progressive, chronic, incurable and can lead to visual impairment and even blindness if not adequately treated. Treatment is aimed at managing the disease, in order to reduce the severity of symptoms and to slow progression, rather than being curative.

Scientific advancements over recent decades have revealed a broad range of novel potential molecular targets, enabling progress in a previously stagnant field. This is reflected by the high number of products in development, with 782 pipeline products currently in the ophthalmology therapy area pipeline.

Moreover, there are a total of 158 first-in-class pipeline products in development for ophthalmology indications, representing 36% of the 438 pipeline products for which there is a disclosed molecular target. They appear generally promising in terms of safety and efficacy, and appear to have significant potential to strengthen the treatment landscape for key

ophthalmological conditions - as well as representing promising commercial opportunities.

Many first-in-class products in the current ophthalmology pipeline have previously been involved in licensing and co-development deals. This indicates a strong degree of strategic consolidation uptake for first-in-class products in ophthalmology, and a willingness on the part of companies to invest in innovative products that show promise in both preclinical and clinical trials.

Scope

- Analysis of innovation in the ophthalmology markets in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape surrounding first-in-class products in ophthalmology, and highlights opportunities for in-licensing. Key indications covered in detail include glaucoma, age-related macular degeneration, diabetic retinopathy and diabetic macular edema.
- A brief introduction to ophthalmology, including symptoms, pathophysiology, and an overview of pharmacotherapy for the key diseases.
- The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
- Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
- Assessment of the licensing and co-development deal landscape for ophthalmology therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.

Reasons to buy

- Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
- Visualize the composition of the ophthalmology market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
- Analyze the ophthalmology pipeline, stratified by indication, stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify commercial opportunities in the ophthalmology deals landscape by analyzing trends in licensing and co-development deals, and producing a list of ophthalmology therapies that are not yet involved in deals and may be potential investment opportunities.

Table of Contents

1 Table of Contents 2

1.1	List of Tables	3
1.2	List of Figures	3
2	Executive Summary	5
2.1	Market Landscape Poised for Entry of Novel Products	5
2.2	Moderately-Sized but Strong First-in-Class Pipeline	5
2.3	Strong Uptake of First-in-Class Products in Strategic Consolidations	5
3	The Case for Innovation	6
3.1	Growing Opportunities for Biologic Products	7
3.2	Diversification of Molecular Targets	7
3.3	Innovative First-in-Class Product Development Remains Attractive	7
3.4	Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation	8
3.5	Sustained Innovation	8
4	Clinical and Commercial Landscape	9
4.1	Therapy Area Overview	9
4.1.1	Glaucoma	9
4.1.2	Age-related Macular Degeneration	9
4.1.3	Diabetic Macular Edema	9
4.1.4	Diabetic Retinopathy	9
4.1.5	Dry Eye Syndrome	10
4.2	Disease Symptoms	10
4.3	Epidemiology and Etiology	12
4.3.1	Glaucoma	12
4.3.2	Age-related Macular Degeneration	12
4.3.3	Diabetic Retinopathy and Diabetic Macular Edema	12
4.3.4	Dry Eye Syndrome	12
4.4	Diagnosis	13
4.5	Pathophysiology	13
4.5.1	Healthy Eye Physiology	13
4.5.2	Glaucoma	14
4.5.3	Age-related Macular Edema	15
4.5.4	Diabetic Macular Edema and Diabetic Retinopathy	16
4.6	Treatment Options	17
4.7	Prognosis	19
4.7.1	Glaucoma	19
4.7.2	Age-Related Macular Degeneration	19
4.7.3	Diabetic Retinopathy and Diabetic Macular Edema	19
4.7.4	Dry Eye Syndrome	20
4.8	Overview of Marketed Products in Ophthalmology	20
4.8.1	Molecule Type and Target Analysis	20
5	Assessment of Pipeline Product Innovation	22
5.1	Ophthalmology Pipeline by Molecular Target	25
5.2	Comparative Distribution of Programs between the Ophthalmology Market and Pipeline by Therapeutic Target Family	28

5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 28

6 Signaling Network, Disease Causation and Innovation Alignment 35

6.1 Complexity of Signaling Networks in Ophthalmology 35

6.2 First-in-Class Matrix Assessment 35

7 First-in-Class Target Evaluation 39

7.1 Pipeline Programs Targeting RPE65 and RBP4 39

7.2 Pipeline Programs Targeting Eotaxin-1 and CCR3 41

Access Report @ <https://www.wiseguyreports.com/reports/744722-frontier-pharmaceuticals-leading-the-way>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/353989695>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.